Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Weekly Update: Telehealth Reversion, Obesity Platform Race Today marks Day One of post-pandemic Medicare telehealth. With Congress failing to extend flexibilities through the weekend, health
GRAIL Galleri PMA, Formation Bio $500M, Summit BLA A structural transition is underway: GRAIL’s PMA submission for Galleri marks a watershed moment for liquid biopsy
Cellares $257M, Regenxbio Hold, Skyhawk Huntington’s High-conviction capital is flooding cell therapy infrastructure as Cellares secures a $257M Series D to industrialize manufacturing. Meanwhile, a
UnitedHealth Crashes 20%, Intellia Hold Lifted | Jan 2026 A structural repricing of the managed care sector (-20% UNH) following disappointing Medicare Advantage rates and
Tuesday Brief: Capital Gets Conditional Monday’s session reinforced a “Capital Gets Conditional” regime: multi-year clinical durability (Sarepta) and clear regulatory differentiation (Guardant) are being rewarded,
Last week confirmed a shift from asset acquisition toward structured optionality, with milestone-heavy dealmaking in oncology and immunology accelerating alongside FDA clearances that reinforce momentum
Big Pharma business development and late-stage venture capital converged today around differentiated platforms. Bristol Myers Squibb committed $850 million to tumor-activated T-cell engagers through a
IntraBio’s pivotal Phase 3 success in ataxia-telangiectasia validates a viable registrational path for functional endpoints in ultra-rare disease, while the FDA’s draft guidance on minimal
Celcuity’s Priority Review for gedatolisib establishes a July 17 PDUFA date in HR+/HER2- breast cancer, creating a hard anchor for the competitive landscape in the
U.S. markets return from the MLK holiday today to face the “JPM Bill.” Late Friday, the sector priced nearly $2.5 billion in secondary equity, led
